38897 - Neuroendocrine Cancer (Answered)

Mr Nicholas Brown
To ask the Secretary of State for Health, what information his Department holds on the use of peptide receptor radionuclide therapy treatments to target carcinoid tumours.

George Freeman

Information on the peptide receptor radionuclide therapy treatments funded through the Cancer Drugs Fund (CDF) is shown in the table. It is not known for what type of cancer these treatments have been provided.

Number of patients treated in 2011/121

Number of patients treated in 2012/131

Number of CDF notifications 2013/142

Number of CDF notifications 2014/152

Number of CDF notifications 2015/16 (to Sept) 2

Peptide receptor radionuclide therapy (to include Lutetium-177 or Yttrium-90 octreotide analogues)

49

117

152

229

116

1 Source: Strategic Health Authority returns to the Department of Health

2 Source: NHS England

Information on the number of peptide receptor radionuclide therapy treatments provided outside of the CDF is not collected.